Because TCIP3 exhibited cancer-specific cytotoxicity and was less toxic than p300/CBP-targeting agents in untransformed cells, we assessed the generality of these observations by testing the sensitivity of seven different lymphoma and leukemia lines. Here, CREBBP is linked to lymphoma.